Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical ValidationJonathan Dao(The University of Texas at San Antonio Health Science Center), Daruka Mahadevan(The University of Texas MD Anderson Cancer Center)International Journal of Molecular SciencesAugust 25, 202310.3390/ijms241713219Cited by 89SaveCiteExport RISWatch citationsRelated PapersMP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer|BMC Cancer|2009|56Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Blood|2010|2